Aspirin for the primary prevention of cardiovascular events

Medical Journal of Australia

Volumn 177, Issue 7, 2002, Pages 343-344

  Hankey, Graeme J ^a,b   Eikelboom, John W ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

BLEEDING TENDENCY; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MEDICAL DECISION MAKING; PRESCRIPTION; PRIMARY PREVENTION; RELIABILITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; THROMBOSIS;

EID: 0037038192     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2002.tb04833.x     Document Type: Editorial

References (13)

1. Antithrombotic Trialists' Collaborative. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med 2002; 136: 157-160.
3. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
4. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002; 106: 388-391.
5. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-316.
6. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-135.
7. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-241.
8. Hansson L, Zanchetti AZ, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
9. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95.
10. Sudlow C. What is the role of antithrombotic treatment in asymptomatic people? In: Clinical Evidence. 6th Issue. London: BMJ Publishing Group, December 2001: 101-102.
11. Cardiovascular risk assessment tool. Available at: . Accessed 6 September 2002.
12. New Zealand cardiovascular risk calculator. National Prescribing Service Limited. Available at: . Accessed 6 September 2002.
13. Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med 2002; 346: 1468-1474.